NeoGenomics(NEO)
Focus: NeoGenomics is a publicly traded diagnostics company specializing in genetic and diagnostic testing, with ~500-1,000 employees and $592M in FY 2025 revenue. They operate in the rare disease space with a focus on precision medicine applications.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
501-1000
Open Jobs
3
Should You Work at NeoGenomics?
AI assessmentNeoGenomics offers stable, cash-backed diagnostics exposure with rare disease focus, but low R&D intensity and minimal hiring make it better for operations/commercial careers than innovation-driven professionals.
Why Work Here
- Publicly traded stability with $367M cash position and consistent revenue growth ($592M FY2025 vs $510M FY2024, +16% YoY)
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$592M
Pipeline & Clinical Trials
IO102-IO103 in combination with pembrolizumab
Lung Cancer Non Small CellRecent News · NeoGenomics
Help build intelligence for NeoGenomics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.